Compare DexCom, Inc. (DXCM) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Koninklijke Philips NV — how do they compare? DexCom, Inc. trades at $88.94 (market cap $33.79B), while Koninklijke Philips NV trades at $26.67 (market cap $26.58B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Koninklijke Philips NV pays a 3.75% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | PHG | |
|---|---|---|
Market Cap | $33.79B | $26.58B |
Sector | Health | Health |
52-Week High | $89.53 | $32.91 |
52-Week Low | $54.84 | $25.02 |
Enterprise Value | $33.24B | $33.13B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
PHG trades at $26.94, up 0.79% with bullish technical signals and strong earnings beats in recent quarters. The company shows improving fundamentals with 2025 net income of $895M (5.01% margin) and positive cash flow trends. Recent news highlights Exor's increased stake flexibility and institutional buying interest, supporting positive sentiment despite some order timing challenges.
The outlook remains constructive with analyst consensus leaning positive (40.9% buy ratings) and improving profitability. Key risks include competitive pressures and macroeconomic headwinds, but solid execution and shareholder support provide stability for medium-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
